



**WEDNESDAY, 11<sup>th</sup> OCTOBER 2017 COMMENCING 09:30 AM**  
**AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST**  
**LLANEDYRN, CARDIFF, CF23 9XF**

## **AGENDA**

- |                                       |                  |
|---------------------------------------|------------------|
|                                       | <b>Enclosure</b> |
| 1. <b>Welcome and introduction</b>    |                  |
| 2. <b>Apologies</b>                   |                  |
| 3. <b>Declarations of interest</b>    |                  |
| 4. <b>Minutes of previous meeting</b> | 1/AWMSG/1017     |

***To protect commercial confidentiality the following appraisals will be held in private***

- |  |                            |
|--|----------------------------|
| 5. <b>Appraisal 1: Full Submission (WPAS)</b><br><b>Lenvatinib (Lenvima<sup>®</sup>)</b> for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)  | 2/AWMSG/1017<br>Appendices |
| 6. <b>Appraisal 2: Full Submission (WPAS)</b><br><b>Glecaprevir/pibrentasvir (Maviret<sup>®</sup>)</b> for the treatment of chronic hepatitis C virus infection in adults  | 3/AWMSG/1017<br>Appendices |
| 7. <b>Appraisal 3: Limited Submission (WPAS)</b><br><b>Dolutegravir (Tivicay<sup>®</sup>)</b> in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged 6 - 12 years   | 4/AWMSG/1017<br>Appendices |
| 8. <b>Appraisal 4: Limited Submission</b><br><b>C1 inhibitor (human) (Cinryze<sup>®</sup>)</b> for the treatment and pre-procedure prevention of angioedema attacks in children aged 2–11 years with hereditary angioedema (HAE); routine prevention of angioedema attacks in children aged 6–11 years with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment | 5/AWMSG/1017<br>Appendices |

**The meeting will now open to the public**

- |   |  |
|---|--|
| 9. <b>Chairman's report (verbal update)</b> |  |
|---|--|

10. **Appraisal 5: Full Submission** 6/AWMSG/1017  
**5-aminolevulinic acid (Ameluz®)** for the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults Appendices
11. **Appraisal 6: Full Submission (Re-submission)** 7/AWMSG/1017  
**Tiotropium (Spiriva® Respimat®)** as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids ( $\geq 800$   $\mu\text{g}$  budesonide/day or equivalent) and long-acting  $\beta 2$  agonists and who experienced one or more severe exacerbations in the previous year Appendices
12. **Medicines Identified as Low Priority for Funding in NHS Wales** 8/AWMSG/1017

**Date of next meeting – Wednesday, 8<sup>th</sup> November 2017 in Cardiff**